3-(2,4,5-trimethoxyphenyl)propionic acid | 125438-30-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(2,4,5-trimethoxyphenyl)propionic acid
• 英文别名: 3-(2,4,5-Trimethoxy-phenyl)-propionic acid；3-(2,4,5-trimethoxyphenyl)propanoic acid
• CAS: 125438-30-4
• 化学式: C₁₂H₁₆O₅
• mdl: MFCD09943179
• 分子量: 240.256
• InChiKey: UGHPWKLKDZLPNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(2,4,5-trimethoxyphenyl)propionic acid 在 四氧化锇 、 lithium aluminium tetrahydride 、 正丁基锂 、 三甲基乙酰氯 、 N-甲基吗啉氧化物 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 20.58h， 生成 (3R)-4-(benzyloxy)-3-(2,4,5-trimethoxybenzyl)-1-(2,4,5-trimethoxyphenyl)butan-1-ol
  参考文献：
  名称：

  (-)-Magnoshinin 和 (+)-Merrilliaquinone 的全合成：后期氧化功能化方案的应用

  摘要：

  使用 DDQ 的后期氧化功能化和随后的化学选择性氧化去甲基化能够合成 (-)-magnoshinin 和 (+)-merrilliaquinone。

  DOI：

  10.1002/ejoc.202101452
• 作为产物：
  描述：

  2,4-dihydroxy-5-methoxycinnamic acid 在 甲醇 、 氢氧化钾 、 sodium amalgam 、 溶剂黄146 作用下， 生成 3-(2,4,5-trimethoxyphenyl)propionic acid
  参考文献：
  名称：

  Moore, Journal of the Chemical Society, 1911, vol. 99, p. 1044

  摘要：

  DOI：

文献信息

• [EN] TREATMENT OF FABRY DISEASE<br/>[FR] TRAITEMENT DE LA MALADIE DE FABRY
  申请人：ACADEMIA SINICA

  公开号：WO2017222881A1

  公开（公告）日：2017-12-28

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with -COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文揭示了聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗患有或疑似患有FD的受试者的方法。该方法包括步骤，向受试者施用化合物I式，其盐、酯或溶剂化物的治疗有效量，其中：R1是H，或C1-3胺，可选地取代为-COR2；R2是烷基或烯烃，可选地取代为环烷基或苯基，其至少有一个取代基选自卤素，烷基，卤代烷基和烷氧基的群体；以缓解、减轻和/或预防与FD相关的症状。根据本公开的优选实施例，化合物I式是人类溶酶体α-半乳糖苷酶A（α-Gal A）的突变体的伴侣蛋白。
• Antioxidants
  申请人：Rudolph Thomas

  公开号：US20080152603A1

  公开（公告）日：2008-06-26

  The present invention relates to the use of compounds of the formula (I), with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

  本发明涉及使用式(I)中定义的基团化合物作为抗氧化剂，涉及对应的新型化合物和组合物，以及制备这些化合物和组合物的对应过程。
• Uv Protection
  申请人：Rudolph Thomas

  公开号：US20080171004A1

  公开（公告）日：2008-07-17

  The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

  本发明涉及使用那些本身在UV-A或UV-B区域不表现出显著UV吸收但在使用条件下具有反应性的化合物用于开发UV-A或UV-B保护，以及相应的新化合物和组合物，以及制备化合物和组合物的相应过程。
• Treatment of Fabry disease
  申请人：Academia Sinica

  公开号：US10995067B2

  公开（公告）日：2021-05-04

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文公开了一种聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗法布里病或疑似法布里病受试者的方法。该方法包括以下步骤：向受试者施用治疗有效量的式(I)化合物、其盐、酯或溶液，其中：R1是H，或任选被-COR2取代的C1-3胺；R2是烷基或烯基，任选被环烷基或苯基取代，环烷基或苯基具有至少一个选自由卤代、烷基、卤代烷基和烷氧基组成的组的取代基；从而改善、减轻和/或预防与FD相关的症状。根据本公开的优选实施方案，式（I）化合物是突变的人溶酶体 α-半乳糖苷酶 A（α-Gal A）的合子。
• Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease
  作者：Wei-Chieh Cheng、Jen-Hon Wang、Wen-Yi Yun、Huang-Yi Li、Jia-Ming Hu

  DOI：10.1016/j.ejmech.2016.10.004

  日期：2017.1

  The rapid discovery of a pharmacological chaperone toward human alpha-Gal A for the treatment of Fabry disease is described. Two polyhydroxylated pyrrolidines with the (3R,4S,5R) configuration pattern underwent rapid substituent diversity by conjugating the primary aminomethyl moiety of each with a variety of carboxylic acids to generate two libraries (2 x 60 members). Our bioevaluation results showed one member with the (2R,3R,4S,5R) configuration pattern and bearing a 5-cyclohexylpentanoyl group as a substituent moiety possessed sufficient chaperoning capability to rescue alpha-Gal A activity in the lymphocyte of the N215S Fabry patient-derived cell line and other alpha-Gal A mutants in COS7 cells. (C) 2016 Elsevier Masson SAS. All rights reserved.